- Q3 revenue climbed 53% YoY to $26.1 million with net cash use declining to $0.6 million.
- Full-year 2026 revenue guidance raised to $92M–$94M from $86M–$89M.
- Reaffirmed expectation of reaching cash flow breakeven in Q4 2026.
Signal #151902 · SEC 8-K
$RCEL SEC Filing Alert & Real-Time AI Stock Impact Analysis
Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).
FAQ: $RCEL filing catalyst
Why did $RCEL trigger an AI stock catalyst alert?
$RCEL triggered a Stock Catalyst AI alert on 2026-11-05 00:00:00 UTC for a SEC 8-K filing (AI Score: +6.5/10). Headline: AVITA Medical Reports 53% Q3 Revenue Growth, Raises Full-Year 2026 Guidance. Key points: - Q3 revenue climbed 53% YoY to $26.1 million with net cash use declining to $0.6 million. - Full-year 2026 revenue guidance raised to $92M–$94M from $86M–$89M. - Reaffirmed expectation of reaching cash flow breakeven in Q4 2026.
How did $RCEL stock react after the SEC filing?
After the SEC 8-K for $RCEL, observed market reaction: T0 price $15.68. Past moves do not guarantee future results.
Where can I get real-time $RCEL SEC filing alerts?
Stock Catalyst AI pushes real-time SEC 8-K alerts for $RCEL via Telegram and the VIP Web Terminal from €10/month.